Stabilized Endolysin Cereal Meal Dermatitis Treatment

The patent changes the physical state of the endolysin from aqueous solution to lyophilized powder form, and modifies the environmental parameters by incorporating it into a cereal meal matrix. This parameter change transforms the unstable aqueous solution into a stable solid formulation that maintains activity upon reconstitution, directly resolving the stability-duration contradiction.

The cereal meal acts as an intermediary carrier that protects the endolysin protein from degradation. The matrix provides a protective environment that stabilizes the protein structure, allowing it to maintain its lytic activity over extended periods while remaining deliverable as a topical treatment for dermatitis.

The patent converts the harmful effect of bacterial infection in dermatitis into a beneficial treatment opportunity by using bacteriophage endolysins. These phage-derived enzymes specifically target and lyse bacterial cell walls, transforming the pathogenic bacterial presence into a therapeutic mechanism that eliminates the underlying cause rather than merely suppressing symptoms with steroids.

The treatment employs highly specific local action where endolysins target only the pathogenic bacteria responsible for dermatitis exacerbation. This specificity ensures that beneficial bacteria and host tissues are unaffected, eliminating the broad-spectrum harmful effects associated with conventional antibiotic and steroid treatments while maintaining effective anti-inflammatory and antibacterial activity.

The endolysin treatment exhibits highly specific local quality by targeting only bacteria with specific cell wall structures. This specificity allows selective elimination of pathogenic bacteria while preserving beneficial flora, as the enzymatic action is restricted to matching bacterial targets through structure-activity relationships of the phage-derived enzymes.

The patent converts the presence of pathogenic bacteria, which cause harm in dermatitis, into a beneficial therapeutic target. The bacteriophage endolysins are designed to specifically recognize and lyse these pathogenic bacteria, transforming the harmful bacterial population into the basis for selective eradication while sparing beneficial microbes that lack the appropriate cellular targets.